biliary
No description yet: the sentence for this tag has not been written. 8 records carry it: 7 people, 1 cancer.
Related tags
8 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
Andrew X. Zhu Hepatobiliary medical oncologist and trial lead Oncologist who led REACH-2, the first positive biomarker-selected trial in liver cancer, which established ramucirumab for patients with a high alpha-fetoprotein level. | Advanced hepatocellular carcinoma, Hepatocellular carcinoma, Intrahepatic cholangiocarcinoma | none | hcc, trialist | ||
Angela Lamarca Medical oncologist, biliary tract and neuroendocrine cancers Oncologist who was lead author of ABC-06, the first randomised trial to show that second-line chemotherapy helps people with advanced bile duct cancer. | Biliary tract cancer, Biliary tract cancer, Neuroendocrine tumours | none | trialist | ||
Gallbladder cancer Gallbladder cancer is a biliary tract cancer of the bile-storing sac under the liver, most often found by chance when the gallbladder is removed for stones. Caught early, a second operation to clear the liver bed and nodes can cure it; for advanced disease, chemotherapy now comes with an immunotherapy partner, and HER2-directed antibodies help the subset whose tumours over-express HER2. | none | none | rare, gastrointestinal | ||
Ghassan K. Abou-Alfa Attending Physician, Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led HIMALAYA and ClarIDHy, which gave liver cancer a dual-immunotherapy option and biliary cancer its first targeted drug. | Hepatocellular carcinoma, Biliary tract cancer | none | hcc, trialist | ||
John N. Primrose Professor of Surgery, University of Southampton · University Hospital Southampton / Centre for Cancer Immunology British surgeon who led BILCAP, the trial that made six months of capecitabine the standard after surgery for bile duct and gallbladder cancer. | Extrahepatic cholangiocarcinoma, Intrahepatic cholangiocarcinoma, Biliary tract cancer | none | surgery, trialist | ||
Juan W. Valle Chief Medical Officer, Cholangiocarcinoma Foundation; Honorary Professor of Medical Oncology, University of Manchester and The Christie · The Christie NHS Foundation Trust Led ABC-02, which made gemcitabine plus cisplatin the global standard for biliary cancer, and co-led TOPAZ-1. | Biliary tract cancer | none | chemotherapy, trialist | ||
Lipika Goyal Associate Professor of Medicine and Director of Gastrointestinal Oncology, Stanford Cancer Institute · Stanford Health Care / Stanford Cancer Institute Led the futibatinib trial and defined how FGFR2-driven bile duct cancers become resistant to targeted drugs. | Biliary tract cancer | none | fgfr2, targeted-therapy | ||
Robin Kate Kelley Gastrointestinal oncologist, UCSF Helen Diller Family Comprehensive Cancer Center · UCSF Helen Diller Family Comprehensive Cancer Center San Francisco oncologist who was lead author of KEYNOTE-966, which showed that adding pembrolizumab to gemcitabine and cisplatin helps people with advanced bile duct cancer live longer. | Intrahepatic cholangiocarcinoma, Biliary tract cancer, Hepatocellular carcinoma | none | hcc, immunotherapy, trialist |